United for Health Equity - Living PDX Program (U4HELPP)

United for Health Equity - Living PDX 计划 (U4HELPP)

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT – OVERALL The United for Health Equity-Living PDX Program (U4HELPP) seeks to develop >500 new patient-derived xenograft (PDX) models of cancers originated from the breast, pancreas, colon, liver, lung, and other advanced peritoneal cancers. These PDXs will be made from >60% of patients from underrepresented populations which our safety-net clinical system serves. To develop such a large number and diverse set of PDXs, we have enlisted the support of a set of surgeons that specialize in each cancer type. Once extracted, the tumors are immediately provided to the U4HELPP PDX Core which functions to propagate, distribute, and cryopreserve them. Successfully generated PDXs will be subjected to genomic characterization and quantitative ancestral profiling by the U4HELPP Bioinformatics Core so that we can better understand how ancestry contributes to genetics and responses to targeted therapeutics. The PDXs will be provided to two Research Projects, that will focus on either pancreatic cancer or breast cancer. The Pancreatic Cancer project will generate large-scale proteomics insights from over 200 PDXs to refine subtypes of the disease and identify more effective therapeutics from Black and White patients. The Breast Cancer project will utilize 20 PDXs that are Basal-like breast cancers, characterize their metastatic profiles, define proteogenomic pathways that mediate metastatic growth, and target metastases with synergistic investigational new drug combinations. The information from these PDXs and Projects will be shared with the U4HELPP Pilot Projects and Trans-Network Activities Core which will award Pilot Project grants to utilize the PDXs generated by us and our partnering PDXNet institutions. All of the PDXs and insights gained will be shared with the NCI with the goal of reducing cancer disparities. Through this team effort we are confident that we will be able to develop these unique resources and generate significant preliminary data that will support investigator initiated clinical trials at the Massey Cancer Center.
项目总结/摘要-总体 联合健康公平生活PDX计划(U4 HELPP)旨在开发超过500个新的患者衍生 本发明提供了源自乳腺癌、胰腺癌、结肠癌、肝癌、肺癌和其他晚期癌症的异种移植(PDX)模型。 腹膜癌这些PDX将由来自代表性不足的人群的>60%的患者制成, 我们的安全网临床系统服务。为了开发如此大量和多样化的PDX,我们招募了 一组专门治疗每种癌症的外科医生的支持。一旦取出肿瘤, 提供给U4 HELPP PDX核心,其功能是繁殖、分发和冷冻保存它们。 成功生成的PDX将进行基因组表征和定量祖先分析 通过U4 HELPP生物信息学核心,我们可以更好地了解祖先如何对遗传学做出贡献 和对靶向治疗的反应。PDX将提供给两个研究项目,重点是 不是胰腺癌就是乳腺癌胰腺癌项目将产生大规模的蛋白质组学 来自200多个PDX的见解,以细化疾病的亚型,并从Black 和白色患者。乳腺癌项目将利用20种基底样乳腺癌PDX, 描述其转移特征,定义介导转移生长的蛋白基因组学途径,并靶向 与协同研究性新药组合的转移。这些PDX的信息, 项目将与U4 HELPP试点项目和跨网络活动核心共享,后者将奖励试点项目。 项目赠款,以利用我们和我们的PDXNet合作机构产生的PDX。所有的PDX和 所获得的见解将与NCI分享,以减少癌症差异。通过这个团队的努力 我们有信心,我们将能够开发这些独特的资源,并产生重大的初步 这些数据将支持研究者在梅西癌症中心发起的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joshua (Chuck) Harrell其他文献

Joshua (Chuck) Harrell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joshua (Chuck) Harrell', 18)}}的其他基金

Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
  • 批准号:
    10733315
  • 财政年份:
    2023
  • 资助金额:
    $ 103.1万
  • 项目类别:
Characterization of metastasis models derived from breast cancer patients of African descent
非洲裔乳腺癌患者转移模型的表征
  • 批准号:
    10669268
  • 财政年份:
    2022
  • 资助金额:
    $ 103.1万
  • 项目类别:
Characterization of metastasis models derived from breast cancer patients of African descent
非洲裔乳腺癌患者转移模型的表征
  • 批准号:
    10510244
  • 财政年份:
    2022
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10159229
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10714928
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10652411
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
Circumventing acquired carboplatin resistance in triple-negative breast cancers
规避三阴性乳腺癌的获得性卡铂耐药性
  • 批准号:
    10441272
  • 财政年份:
    2020
  • 资助金额:
    $ 103.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了